Addition of isoprenoid lipids (prenylation) is critical from the activity of a number of enzymes that play essential roles in signal transduction pathways or membrane trafficking. Three protein prenyl transferases have been identified; a farnesyl transferase (FTase) which adds a 15-carbon isoprenoid, and two geranylgeranyl transferases (GTase-I, and -II) which add a 20-carbon isoprenoid. FTases and GTase-I modify a conserved cysteine residue located in a C-terminal tetrapeptide (""""""""CAAX"""""""" motif) of the modified protein. Prenylation of a number of small regulatory G proteins activate and target these to their cell membranes. Of particular medical relevance is the recent observation that Ras oncogen proteins are farnesylated. This modification is absolutely required for the transforming activity this protein. Treatment of Ras transformed cells with inhibitors to FTase has been shown to result in reversion of the transformed phenotype in tissue culture cells. Inhibition of Ras farnesylation is currently considered one of the most promising anti-cancer targets. Roughly 30% of human carcinomas are associated with oncogenic forms of Ras. Elucidation of the three dimensional structure of FTase is therefore important both for understanding fundamental processes in signal transduction and for the development of anti-cancer drugs or derivatives of existing drugs. The goal of this proposal is to understand the mechanism and substrate specificity of protein prenyl transferase proteins in terms of their three- dimensional structure.
The specific aims are summarized as follows: 1. To determine and refine the three-dimensional structures of farnesyl transferase together with appropriate substrate complexes by X-ray crystallography. Crystals of mammalian FTase and FTase with a bound peptide substrate have been grown that diffract to better than 2.5 A resolution and a native date set has been collected. To our knowledge this is the first prenyl transferase enzyme crystallized. The structure will provide a basis for understanding and interpreting biochemical and biophysical data on protein prenylation. 2. To determine the co-crystal structure of a ternary compllex of FTase, peptide substrate, and a farnesyl diphosphate analog. To determine the crystal structures of other complexes of FTase with appropriate substrates and inhibitors: peptides, farnesyl diphosphate, peptidomimetic and other inhibitors. These structures are essential for understanding the catalytic mechanism in atomic detail and determining the nature of substrate specificity. Together these structures provide a structural foundation for the design of improved anti-cancer therapeutics. 3. A long range goal is also to obtain crystals and determine the crystal structure of the GGTase-1 together with appropriate substrate complexes.
| Miller 3rd, Bill R; Beese, Lorena S; Parish, Carol A et al. (2015) The Closing Mechanism of DNA Polymerase I at Atomic Resolution. Structure 23:1609-1620 |
| Hast, Michael A; Nichols, Connie B; Armstrong, Stephanie M et al. (2011) Structures of Cryptococcus neoformans protein farnesyltransferase reveal strategies for developing inhibitors that target fungal pathogens. J Biol Chem 286:35149-62 |
| Fletcher, Steven; Keaney, Erin Pusateri; Cummings, Christopher G et al. (2010) Structure-based design and synthesis of potent, ethylenediamine-based, mammalian farnesyltransferase inhibitors as anticancer agents. J Med Chem 53:6867-88 |
| Hast, Michael A; Fletcher, Steven; Cummings, Christopher G et al. (2009) Structural basis for binding and selectivity of antimalarial and anticancer ethylenediamine inhibitors to protein farnesyltransferase. Chem Biol 16:181-92 |
